Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting - PubMed (original) (raw)
Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting
Ngwana Geraldine et al. Diabetes Res Clin Pract. 2012 Aug.
Abstract
Background: Associations between type 2 diabetic patients and a higher risk of developing cancer have been reported worldwide. Recently, a protective effect of metformin has been described.
Aim: To examine in the Belgian primary care population the relation between presence of type 2 diabetes with and without metformin treatment and the occurrence of malignancies.
Design of study: Retrospective cohort study, based on the Intego database, an ongoing Belgian general practice-based morbidity registry, covering 90 general practitioners and including about 1.5 million patient-years between 1994 and 2008.
Method: Cox proportional hazard analysis comparing emergence of malignancy in patients with and without type 2 diabetes, and among patients with diabetes comparing emergence of malignancy in those treated with various antidiabetic drugs.
Results: Malignancies occurred more in type 2 diabetic patients compared to non-diabetic controls (HR=1.84; 95% CI=1.51-2.24), adjusted for age, gender and weight. Treatment with both metformin and 'other' antidiabetic agents was related to decreased cancer risk (HR=0.24 and 0.22) compared to diet only in men but not in women.
Conclusion: In this Belgian primary care setting, diabetic patients have higher cancer prevalences than non-diabetic patients. Moreover, in diabetic men, not only metformin but also other antidiabetic agents were associated with lower cancer risks.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Comment in
- Links among type 2 diabetes, cancer and metformin use: what have we learned?
Sheen YJ, Sheu WH. Sheen YJ, et al. Diabetes Res Clin Pract. 2012 Aug;97(2):169-71. doi: 10.1016/j.diabres.2012.03.014. Epub 2012 Apr 10. Diabetes Res Clin Pract. 2012. PMID: 22497968 No abstract available.
Similar articles
- Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, Stalla GK, Schmid RM, Kales SN, Mantzoros CS. Baur DM, et al. Metabolism. 2011 Oct;60(10):1363-71. doi: 10.1016/j.metabol.2010.09.012. Epub 2010 Nov 16. Metabolism. 2011. PMID: 21081242 - Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.
Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E, Grassi G. Bo S, et al. Diabetes Obes Metab. 2012 Jan;14(1):23-9. doi: 10.1111/j.1463-1326.2011.01480.x. Epub 2011 Nov 21. Diabetes Obes Metab. 2012. PMID: 21812892 - Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study.
Lin HC, Kachingwe BH, Lin HL, Cheng HW, Uang YS, Wang LH. Lin HC, et al. Pharmacotherapy. 2014 Jan;34(1):36-45. doi: 10.1002/phar.1334. Epub 2013 Jul 17. Pharmacotherapy. 2014. PMID: 23864581 Clinical Trial. - Metformin and cancer.
Rizos CV, Elisaf MS. Rizos CV, et al. Eur J Pharmacol. 2013 Apr 5;705(1-3):96-108. doi: 10.1016/j.ejphar.2013.02.038. Epub 2013 Mar 13. Eur J Pharmacol. 2013. PMID: 23499688 Review. - [Anti-cancer activity of metformin: new perspectives for an old drug].
Beck E, Scheen AJ. Beck E, et al. Rev Med Suisse. 2010 Sep 1;6(260):1601-7. Rev Med Suisse. 2010. PMID: 20853715 Review. French.
Cited by
- Metformin: A Dual-Role Player in Cancer Treatment and Prevention.
Galal MA, Al-Rimawi M, Hajeer A, Dahman H, Alouch S, Aljada A. Galal MA, et al. Int J Mol Sci. 2024 Apr 6;25(7):4083. doi: 10.3390/ijms25074083. Int J Mol Sci. 2024. PMID: 38612893 Free PMC article. Review. - Evaluating Metformin Strategies for Cancer Prevention: A Target Trial Emulation Using Electronic Health Records.
Dickerman BA, García-Albéniz X, Logan RW, Denaxas S, Hernán MA. Dickerman BA, et al. Epidemiology. 2023 Sep 1;34(5):690-699. doi: 10.1097/EDE.0000000000001626. Epub 2023 May 23. Epidemiology. 2023. PMID: 37227368 Free PMC article. - Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs.
Olatunde A, Nigam M, Singh RK, Panwar AS, Lasisi A, Alhumaydhi FA, Jyoti Kumar V, Mishra AP, Sharifi-Rad J. Olatunde A, et al. Cancer Cell Int. 2021 Sep 17;21(1):499. doi: 10.1186/s12935-021-02202-5. Cancer Cell Int. 2021. PMID: 34535145 Free PMC article. Review. - Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis.
Chen CB, Eskin M, Eurich DT, Majumdar SR, Johnson JA. Chen CB, et al. BMC Cancer. 2018 Jan 10;18(1):65. doi: 10.1186/s12885-017-3934-9. BMC Cancer. 2018. PMID: 29320995 Free PMC article. Review. - Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation.
Farmer RE, Ford D, Forbes HJ, Chaturvedi N, Kaplan R, Smeeth L, Bhaskaran K. Farmer RE, et al. Int J Epidemiol. 2017 Apr 1;46(2):728-744. doi: 10.1093/ije/dyw275. Int J Epidemiol. 2017. PMID: 28031313 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials